GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » LT-Debt-to-Total-Asset

Kodiak Sciences (Kodiak Sciences) LT-Debt-to-Total-Asset : 0.15 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kodiak Sciences's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.15.

Kodiak Sciences's long-term debt to total assets ratio increased from Dec. 2022 (0.12) to Dec. 2023 (0.15). It may suggest that Kodiak Sciences is progressively becoming more dependent on debt to grow their business.


Kodiak Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Kodiak Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences LT-Debt-to-Total-Asset Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - 0.07 0.08 0.12 0.15

Kodiak Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.13 0.14 0.15

Kodiak Sciences LT-Debt-to-Total-Asset Calculation

Kodiak Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=71.862/479.372
=

Kodiak Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=71.862/479.372
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kodiak Sciences  (NAS:KOD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Kodiak Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kodiak Sciences (Kodiak Sciences) Business Description

Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
Jason Ehrlich officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth director, 10 percent owner, officer: Chairman, President and CEO 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang officer: See Remarks 2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek director P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016

Kodiak Sciences (Kodiak Sciences) Headlines

From GuruFocus